"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

Radium-223 re-treatment in mCRPC patients shows a low incidence of hematologic and non-hematologic adverse events, including skeletal-related events. The study reported a median overall survival of 16 ...

Darolutamide plus ADT significantly improves radiological progression-free survival in mHSPC, reducing progression or death risk by 46%. The treatment effect is more pronounced in low-volume disease, ...

“Both groups benefited, but it would look like earlier is better if we can treat patients with low-volume disease,” says Fred Saad, MD, FRCS In this video, Fred Saad, MD, FRCS, shares key findings ...

ARPIs provide significant survival benefits in younger mHSPC patients, with a 13% improvement in 5-year overall survival and 21% in progression-free survival. The meta-analysis included data from 11 ...

"The efficacy findings reported to date are 71% any time response," says John A. Taylor III, MD, MS. In this video, John A. Taylor III, MD, MS, shares the design and preliminary findings of the phase ...

"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD. In this video, Gopa Iyer, MD, shares findings from an ...

Talazoparib and enzalutamide combination significantly improved overall survival in mCRPC patients compared to enzalutamide and placebo. The TALAPRO-2 study showed a median overall survival of 45.8 ...